PlaqueTec

Activities: Research & Development

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

PlaqueTec and the Babraham Institute collaborate on the development of a phenotypic screen for coronary artery blood

PlaqueTec and the Abraham Institute have begun collaborations to develop a bespoke phenotypic assay for use in patients with coronary artery disease (CAD), allowing the identification of cell types commonly present in patient samples.
Research & Development

PlaqueTec appoints Dr Tim Brears as CEO

Cambridge firm is pioneering a biomarker-based approach to understanding coronary artery disease
Subscribe now